SCHEMBL26313464

SCHEMBL26313464

CC(=N)SCCCC#CCCSC(=N)N

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 7/20 0.48
NOS3 P29474 4/20 0.48
NOS2 P35228 4/20 0.48
CYP1A2 P05177 5/20 0.45
CYP2C19 P33261 3/20 0.45
HRH4 Q9H3N8 5/20 0.44
TDP1 Q9NUW8 4/20 0.44
ALDH1A1 P00352 2/20 0.44
HRH2 P25021 1/20 0.44
HSD17B10 Q99714 1/20 0.43
MAPT P10636 2/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 2/20 0.38
CYP3A4 P08684 1/20 0.38
APEX1 P27695 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP2D6 P10635 1/20 0.35
BLM P54132 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26313459 0.92 CYP1A2 (0.50) NOS1NOS3NOS2CYP1A2CYP2C19
SCHEMBL26315979 0.90 CYP1A2 (0.54) NOS1NOS3NOS2CYP1A2CYP2C19
SCHEMBL26313462 0.83 HRH4 (0.44) NOS1NOS3NOS2CYP1A2CYP2C19
SCHEMBL26315972 0.82 CYP1A2 (0.63) NOS1NOS3NOS2CYP1A2CYP2C19
SCHEMBL26315975 0.74 HRH4 (0.52) NOS1NOS3NOS2CYP1A2CYP2C19
4-Isothioureidobutyronitrile SCHEMBL20607675 0.71 CYP1A2 (0.50) NOS1NOS3NOS2CYP1A2CYP2C19
4-Isothioureidobutyronitrile SCHEMBL851495 0.70
4-Isothioureidobutyronitrile SCHEMBL851612 0.68 CYP1A2 (0.52) NOS1NOS3NOS2CYP1A2CYP2C19
SCHEMBL9193111 0.67 CYP1A2 (0.71) NOS1NOS3NOS2CYP1A2CYP2C19
Bromide SCHEMBL8582620 0.67 HRH4 (0.77) NOS1NOS3NOS2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF Gacter Inc. (US) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF NOS1, NOS3, NOS2 NOS1 1/4885NOS3 2/4885NOS2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.